The use of eculizumab in gemcitabine induced thrombotic microangiopathy

BACKGROUND: Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Nephrol
Main Authors: Krishnappa, Vinod, Gupta, Mohit, Shah, Haikoo, Das, Abhijit, Tanphaichitr, Natthavat, Novak, Robert, Raina, Rupesh
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5767063/
https://ncbi.nlm.nih.gov/pubmed/29329518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-018-0812-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares